Rat Knee Osteoarthritis (KOA) Models

Knee osteoarthritis (KOA) is a common degenerative joint disease characterized by cartilage degradation, subchondral bone remodeling, and chronic pain, leading to significant disability, particularly in the aging population. HKeyBio offers a well-validated MIA induced KOA model in Sprague-Dawley rats. Monoiodoacetate (MIA) is a glycolysis inhibitor that selectively induces chondrocyte apoptosis, leading to progressive cartilage degeneration and pain-related behaviors. This model recapitulates key human KOA features including joint swelling, altered weight bearing, cartilage matrix loss, and histopathological changes. It provides a robust platform for preclinical efficacy testing of novel disease-modifying osteoarthritis drugs (DMOADs), analgesics, and anti-inflammatory agents.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Clinically relevant – Recapitulates human KOA: cartilage degeneration, joint swelling, and pain-related behaviors.

Quantifiable endpoints – Body weight, knee joint width (caliper measurement), foot load distribution (weight-bearing asymmetry), cartilage matrix staining score (Safranin O/Fast green), histopathology (HE, toluidine blue).

Mechanism-driven – MIA inhibits chondrocyte glycolysis, inducing apoptosis and progressive cartilage degradation, mimicking the metabolic and structural changes in osteoarthritis.

Translational value – Ideal for testing disease-modifying osteoarthritis drugs (DMOADs), analgesics (NSAIDs, opioids), and anti-inflammatory agents.

IND-ready data packages – Studies can be conducted in accordance with GLP principles.

Technical Data & Validation

MIA Induced SD KOA Model

Applications

• Efficacy testing of disease-modifying osteoarthritis drugs (DMOADs) including cathepsin K inhibitors, Wnt pathway modulators, and anabolic agents

• Evaluation of analgesics (NSAIDs, COX-2 inhibitors, opioids, cannabinoids) for osteoarthritis pain

• Target validation for cartilage degradation and pain pathways

• Biomarker discovery (cartilage degradation markers, inflammatory mediators)

• IND-enabling pharmacology and toxicology studies

Model Specifications

Parameter	Specification
Species/Strain	Sprague-Dawley (SD) rat
Induction method	Intra-articular injection of monoiodoacetate (MIA, 1–3 mg in 50 μL saline) into the knee joint
Study duration	1–8 weeks (acute to chronic phases)
Key endpoints	Body weight, knee joint width (caliper), foot load distribution (weight-bearing asymmetry), cartilage matrix staining score (Safranin O/Fast green), histopathology (HE, toluidine blue, OARSI score), optional: mechanical allodynia (von Frey), gait analysis, serum biomarkers (COMP, CTX-II)
Positive control	NSAIDs (e.g., indomethacin) or DMOADs available as reference compounds
Data package	Raw data, analysis reports, histology slides, behavioral data, bioinformatics (optional)

❓ Frequently Asked Questions

Q1: What knee osteoarthritis model do you provide?

A1: We provide a mature monoiodoacetate (MIA)-induced KOA model using Sprague Dawley (SD) rats for preclinical OA research.

Q2: What is the modeling mechanism?

A2: Intra-articular injection of MIA inhibits aerobic glycolysis of chondrocytes and triggers chondrocyte apoptosis. It effectively induces joint degeneration and pain, simulating the pathological features of human knee osteoarthritis.

Q3: What evaluation indicators are used?

A3: We assess body weight and knee joint width clinically. We also detect foot load distribution, calculate OARSI scores, and perform special staining for cartilage pathological analysis.

Q4: What is the experimental cycle?

A4: A single MIA injection is performed on Day 0. The whole experiment lasts 42 days until all observations and tests are completed.

Q5: What are the advantages and applications?

A5: This model has stable lesions, obvious pain symptoms and good repeatability. It is widely used for efficacy screening and mechanism study of anti-osteoarthritis and analgesic drugs.